Clinical trials: Spinal Injections
Amyotrophic Lateral Sclerosis Als
Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis
The goal of the study aims to evaluate the safety and tolerability of a single intrathecal injection of RJK002 in subjects with amyotrophic lateral sclerosis (ALS), and to determine the recommended Phase II dose (RP2D).
- Trial name
- NCT06493279
- Testing
- RJK002 Intrathecal injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- RJK Biopharma Ltd
Acute Spinal Cord Injury
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
This study is non-randomized, multicenter, confirmatory study by intrathecal administration of KP-100IT, code of HGF (Hepatocyte Growth Factor ) formulation for intrathecal injection, in subjects with acute spinal cord injury.
- Trial name
- NCT04475224
- Testing
- KP-100IT
- Where
- 5 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Kringle Pharma, Inc.
Degenerative Disc Disease
Trial for Treating Painful Degenerative Disc Disease
To evaluate and compare two platelet-based treatments of the functional spinal unit spaced 4 weeks apart to sham procedures for the treatment of degenerative disc disease.
- Trial name
- NCT05287867
- Testing
- Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Regenexx, LLC
Spondylitis, Ankylosing
Extension in AS: Sustainability of Benefits, Safety and Tolerability
This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as…
- Trial name
- MEASURE 1 ext (NCT01863732)
- Testing
- Secukinumab
- Where
- 56 sites in United States, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Novartis Pharmaceuticals
Lumbar Degenerative Disc Disease
Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine
The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease.
- Trial name
- MODEL (NCT05516992)
- Testing
- SB-01 For Injection
- Where
- 30 sites in United States
- Volunteers
- 417 people
- Sponsor
- Spine BioPharma, Inc
Detrusor Muscle Hyperactivity
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
The purpose of this study is to determine the efficacy and safety of a single dose of 750 U of Dysport compared to placebo for the improvement in the daily incontinence episode frequency for each administration mode in subjects…
- Trial name
- NCT01357980
- Testing
- Botulinum toxin type A
- Where
- 17 sites in Czechia, France and 3 more
- Volunteers
- 47 people
- Sponsor
- Ipsen
Degenerative Disc Disease
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into…
- Trial name
- HyaluronicAcid (NCT06325566)
- Testing
- Rexlemestrocel-L + HA mixture, Saline
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- Mesoblast, Ltd.
Transverse Myelitis
Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early activity of Q-Cells® transplantation in subjects…
- Trial name
- NCT03887273
- Testing
- Q-Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Q Therapeutics, Inc.
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- ERASURE (NCT01365455)
- Testing
- secukinumab 150 mg
- Where
- 88 sites in United States, Argentina and 10 more
- Volunteers
- 738 people
- Sponsor
- Novartis Pharmaceuticals
Anklyosing Spondylitis
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
This study assessed the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who were tolerant to or had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor
- Trial name
- MEASURE2 (NCT01649375)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 53 sites in United States, Austria and 11 more
- Volunteers
- 219 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects
It is a randomized, double-blinded, single-dose, 2-arm parallel, comparative study to evaluate the pharmacokinetics and safety of BAT2506 Injection vs Simponi in healthy chinese male subjects A total of 182 subjects are planned…
- Trial name
- NCT04152759
- Testing
- Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Ankylosing Spondylitis
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Ankylosing Spondylitis, and to further explore the efficacy…
- Trial name
- NCT05962762
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
Psoriatic Arthritis
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week…
- Trial name
- NCT06640257
- Testing
- SHR-1314 injection
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Spinal Cord Injuries
Safety and Efficacy of Autologous Bone Marrow Stem Cells in Treating Spinal Cord Injury
The projected data related to the burden of spinal cord injuries induced limb paralysis in India is quite alarming. This is attributed to the rapid industrialization and economical development in the country.
- Trial name
- ABMST-SCI (NCT01186679)
- Testing
- laminectomy, Intrathecal
- Where
- India
- Volunteers
- 12 people
- Sponsor
- International Stemcell Services Limited
Spinal Muscular Atrophy
A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients
This study aims to assess the safety and effectiveness of onasemnogene abeparvovec intrathecal injection in spinal muscular atrophy (SMA) patients in clinical practice in Japan.
- Trial name
- NCT07767890
- Where
- 4 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Degenerative Disc Disease, Chronic Lower Back Pain
Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc Disease
The purpose of this study is to assess the safety and the efficacy of an hydrogel (double cross-link microgel - DXM) injection into the intervertebral disc (IVD) space in patients with painful lumbar degenerative disc disease…
- Conditions
- Degenerative Disc Disease, Chronic Lower Back Pain, Discogenic Pain, Intervertebral Disc Degeneration
- Trial name
- DXM gel (NCT04727385)
- Testing
- Double Crosslink Microgel
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Gelmetix
Psoriatic Arthritis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after…
- Trial name
- NCT04109976
- Testing
- Bimekizumab
- Where
- 47 sites in United States, Czechia and 4 more
- Volunteers
- 214 people
- Sponsor
- UCB Biopharma SRL
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Psoriatic Arthritis, Axial Spondyloarthritis
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
- Trial name
- NCT07290036
- Testing
- Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
- Where
- 63 sites in United States, Bulgaria and 4 more
- Volunteers
- 392 people
- Sponsor
- UCB Biopharma SRL
Diphtheria, Tetanus
A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults
This is a single-center, randomized, active-controlled, parallel-group, open-label, phase I study to evaluate safety and immunogenicity of single injection of LBVD or Eupenta co-administered with Imovax Polio in healthy adults.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT03208101
- Testing
- DTP-HepB-IPV-Hib vaccine, DTP-HepB-Hib vaccine & IPV
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- LG Chem